Kyverna Therapeutics, Inc. Stock-Based Compensation
Kyverna Therapeutics, Inc. (KYTX) reported Stock-Based Compensation of $6.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- Kyverna Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.51M, a 39.28% increase year-over-year.
- Kyverna Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.17M, a 46.74% increase year-over-year.
- Kyverna Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.70M, a 95.51% increase year-over-year.
- Kyverna Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.70M, a 20.92% decline year-over-year.
- Kyverna Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $10.08M, a 20.62% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $8.36M, a 276.44% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $2.22M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $6.68M 10-Q · filed 2026-08-11 | $9.38M derived: sum of 3 quarters · filed 2026-08-11 | $12.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $3.17M 10-Q · filed 2026-05-12 | $5.87M derived: sum of 2 quarters · filed 2026-05-12 | $8.57M derived: sum of 3 quarters · filed 2026-05-12 | $11.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $5.40M derived: sum of 2 quarters · filed 2026-03-26 | $7.92M derived: sum of 3 quarters · filed 2026-08-11 | $10.08M 10-K · filed 2026-03-26 |
| 2025-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $5.22M derived: sum of 2 quarters · filed 2026-08-11 | $7.38M 10-Q · filed 2025-11-12 | $8.76M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.68M 10-Q · filed 2026-08-11 | $6.06M derived: sum of 3 quarters · filed 2026-08-11 | $9.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.16M 10-Q · filed 2026-05-12 | $3.54M derived: sum of 2 quarters · filed 2026-05-12 | $6.96M derived: sum of 3 quarters · filed 2026-05-12 | $8.24M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $4.79M derived: sum of 2 quarters · filed 2026-03-26 | $6.08M derived: sum of 3 quarters · filed 2026-03-26 | $8.36M 10-K · filed 2026-03-26 |
| 2024-09-30 | $3.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.70M derived: sum of 2 quarters · filed 2025-11-12 | $6.97M 10-Q · filed 2025-11-12 | $7.76M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.56M 10-Q · filed 2025-08-12 | $4.35M derived: sum of 3 quarters · filed 2025-08-12 | $4.87M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.28M 10-Q · filed 2025-05-13 | $3.06M derived: sum of 2 quarters · filed 2025-05-13 | $3.58M derived: sum of 3 quarters · filed 2025-05-13 | $4.03M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $784.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.30M derived: sum of 2 quarters · filed 2025-03-27 | $1.75M derived: sum of 3 quarters · filed 2025-03-27 | $2.22M 10-K · filed 2025-03-27 |
| 2023-09-30 | $521.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $968.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.44M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $447.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $915.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $468.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |